Medifast, Inc.
MEDNYSEConsumer Cyclical● Active
$12.19
+$0.09(+0.74%)
Market Cap$135541829
P/E Ratio—
52W High$15.46
52W Low$9.22
Medifast, Inc. (MED) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MED · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.19
Est. -$0.55 · +65.5%
Revenue
$0.08B
Est. $0.07B · +9.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
MED reports quarterly as a NYSE-listed Personal Products & Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.68 | — | — | — | $0.07B | — |
| ▲ Q2 FY2026 | May 4, 2026 | -$0.55 | -$0.19 | +65.5% | $0.08B | $0.07B | +9.9% |
| ▲ Q1 FY2026 | Feb 17, 2026 | -$0.76 | -$0.55 | +27.6% | $0.08B | $0.07B | +5.2% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -$0.01 | -$0.21 | -2000.0% | $0.09B | $0.07B | +25.2% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$0.30 | $0.04 | +113.3% | $0.11B | $0.09B | +12.5% |
| ▼ Q2 FY2025 | Apr 28, 2025 | -$0.07 | -$0.11 | -57.1% | $0.12B | $0.10B | +20.4% |
| ▲ Q1 FY2025 | Feb 18, 2025 | -$0.16 | $0.10 | +162.5% | $0.12B | $0.11B | +4.2% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.15 | $0.35 | +333.3% | $0.14B | $0.11B | +22.7% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.68
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.55
EPS Surpr.
+65.5%
Revenue
$0.08B
Q1 FY2026
Feb 17, 2026Beat
EPS Actual
-$0.55
EPS Est.
-$0.76
EPS Surpr.
+27.6%
Revenue
$0.08B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.01
EPS Surpr.
-2000.0%
Revenue
$0.09B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$0.04
EPS Est.
-$0.30
EPS Surpr.
+113.3%
Revenue
$0.11B
Q2 FY2025
Apr 28, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.07
EPS Surpr.
-57.1%
Revenue
$0.12B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
$0.10
EPS Est.
-$0.16
EPS Surpr.
+162.5%
Revenue
$0.12B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$0.35
EPS Est.
-$0.15
EPS Surpr.
+333.3%
Revenue
$0.14B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q2 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q1 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.62 | $-0.62 | $-0.62 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 4, 2026 | +65.5% | $10.91 | $10.63 | -2.57% |
| ▲ Q1 FY2026 | Feb 17, 2026 | +27.6% | $10.77 | $10.80 | +0.28% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -2000.0% | $12.02 | $11.88 | -1.16% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +113.3% | $13.75 | $13.51 | -1.75% |
| ▼ Q2 FY2025 | Apr 28, 2025 | -57.1% | $12.34 | $12.58 | +1.94% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +162.5% | $16.21 | $16.13 | -0.49% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +333.3% | $18.58 | $18.81 | +1.24% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +155.6% | $21.47 | $20.86 | -2.84% |
Q2 FY2026-2.57%
Report Date
May 4, 2026
EPS Beat/Miss
+65.5%
Price Before
$10.91
Price After
$10.63
Q1 FY2026+0.28%
Report Date
Feb 17, 2026
EPS Beat/Miss
+27.6%
Price Before
$10.77
Price After
$10.80
Q4 FY2025-1.16%
Report Date
Nov 3, 2025
EPS Beat/Miss
-2000.0%
Price Before
$12.02
Price After
$11.88
Q3 FY2025-1.75%
Report Date
Aug 4, 2025
EPS Beat/Miss
+113.3%
Price Before
$13.75
Price After
$13.51
Q2 FY2025+1.94%
Report Date
Apr 28, 2025
EPS Beat/Miss
-57.1%
Price Before
$12.34
Price After
$12.58
Q1 FY2025-0.49%
Report Date
Feb 18, 2025
EPS Beat/Miss
+162.5%
Price Before
$16.21
Price After
$16.13
Q4 FY2024+1.24%
Report Date
Nov 4, 2024
EPS Beat/Miss
+333.3%
Price Before
$18.58
Price After
$18.81
Q3 FY2024-2.84%
Report Date
Aug 5, 2024
EPS Beat/Miss
+155.6%
Price Before
$21.47
Price After
$20.86
Avg Beat Reaction-1.02%
Avg Miss Reaction+0.39%
Beat Rate6 / 8 quarters
Largest Move-2.84% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MED ends December
Medifast, Inc. (MED) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.55 by +65.5%. MED has beaten EPS estimates for 2 consecutive quarters. The next MED earnings date is expected around September 1, 2026.
Each quarter, investors track MED earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MED revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MED's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MED earnings · 5 questionsMedifast, Inc.'s next earnings report is expected around September 1, 2026. MED typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MED historically reports after market close (AMC).
MED earnings datewhen is MED earningsMED next earnings datewhen does MED report earningsMED earnings calendar
▸ Source: FMP · Medifast, Inc. SEC filings · US GAAP · Medifast, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026